A Phase 2 interventional study of Naproxen and Loratadine in Bone Pain in Stage I - III Breast Cancer, sponsored by Amgen. Completed at 83 sites in United States. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-01-30.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Breast Neoplasms by Amgen — none open to participants now, 1 under way, 1 of them phase 3. Breast Neoplasms · Amgen.
Among the 30 studies in Breast Neoplasms by Amgen, this one is the 7th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2012, is one of 12 in phase 2, and was the 24th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 30 studies in Breast Neoplasms by Amgen is open now. The open studies under Breast Neoplasms, anywhere →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,575 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 72 across 10,914 interventional studies indexed under Breast Neoplasms.
Median enrollment 252 across the 21 interventional studies, 1,135 across the 4 observational. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Breast Neoplasms by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.
In this study, the investigational products are naproxen, a non-steroidal antiinflammatory drug (NSAID), and loratadine, an anti-histamine. Both agents are being investigated as prophylactic medications to reduce the incidence and/or severity of bone pain in breast cancer patients receiving adjuvant or neoadjuvant myelosuppressive chemotherapy and pegfilgrastim prophylaxis.
Pegfilgrastim treatment is used to stimulate bone marrow to produce more neutrophils to help fight infections in patients undergoing chemotherapy.
Age 18 years or over
Exclusion Criteria
History of other within the past 5 years, with the following exceptions:
Chronic use of oral non-steroidal anti-inflammatory drug (NSAIDs) or oral antihistamines outside of those dictated by the randomization groups outlined in the protocol, with the following exception:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
Drug: Naproxen · Biological: Pegfilgrastim · Drug: Chemotherapy
Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
Drug: Loratadine · Biological: Pegfilgrastim · Drug: Chemotherapy
Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
Biological: Pegfilgrastim · Drug: Chemotherapy
Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Also known as: Neulasta®
The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Percentage of Participants With Bone Pain (All Grades) in Cycle 1
Bone pain data were captured as part of standard adverse event (AE) reporting.
Time frame: Cycle 1 (approximately 4 weeks, depending on the chemotherapy dosing interval)
Percentage of Participants With Bone Pain (All Grades) by Cycle (2-4) and Across Cycles
Bone pain data were captured as part of standard adverse event (AE) reporting.
Time frame: Cycles 1, 2, 3 and 4 (approximately 4 weeks each, depending on the chemotherapy dosing interval)
Percentage of Participants With Severe Bone Pain by Cycle and Across Cycles
Bone pain data were captured as part of standard adverse event reporting. Severe bone pain is defined as grade 3 or 4 according to common terminology criteria for adverse events (CTCAE) version 3 grading criteria: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening or disabling.
Time frame: Cycles 1, 2, 3 and 4 (approximately 4 weeks each, depending on the chemotherapy dosing interval)
Mean Patient-reported Bone Pain by Cycle and Across Cycles
Participants completed a brief bone pain survey once per day for 5 days beginning the day they received their pegfilgrastim injection. The bone pain survey collected the severity of pain using a 0 (no pain) to 10 (worst pain) scale. Mean patient-reported bone pain values are the average of each participant's bone pain values across survey days 1-5 within each cycle. Across all cycles the mean is the average of each patient-reported bone pain value across all survey days 1-5 and across all cycles. An analysis of variance (ANOVA) model with treatment as explanatory term was used.
Time frame: Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
Maximum Patient-reported Bone Pain by Cycle and Across Cycles
Participants completed a brief bone pain survey once per day for 5 days beginning the day they received their pegfilgrastim injection. The bone pain survey collected the severity of pain using a 0 (no pain) to 10 (worst pain) scale. Maximum patient-reported bone pain is the maximum of each participant's bone pain values across survey Days 1-5 within each cycle. Across all cycles the maximum is the maximum of each patient-reported bone pain value across all survey days 1-5 and across all cycles. An ANOVA model with treatment as explanatory term was used.
Time frame: Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
Area Under the Curve (AUC) for Patient-reported Bone Pain
Patient-reported bone pain AUC was calculated using the trapezoidal rule with bone pain scores from day 1 to 5 for each cycle. The AUC across cycles is the average of AUCs across the cycle.
Time frame: Five consecutive days during each cycle beginning on the day of pegfilgrastim administration (Day 2, 3, or 4 of each cycle)
Number of Participants With Adverse Events (AEs)
Severity was graded using CTCAE version 3. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal; • life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • congenital anomaly/birth defect; • other medically important serious event. The investigator assessed each adverse event for relatedness to investigational product(s) or other protocol-required therapies.
Time frame: From first dose of investigational product (IP, naproxen or loratidine) or first dose of pegfilgrastim (Peg), whichever occurred first, until 30 days after last dose, up to 24 weeks.
This study was conducted at 83 centers in the United States. The first participant enrolled on 01 November 2012 and the last participant enrolled on 20 November 2014.
| Milestone | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Started | 198 | 200 | 202 |
| Received pegfilgrastim | 191 | 196 | 200 |
| Received naproxen / loratadine | 0 | 193 | 198 |
| Completed | 160 | 171 | 181 |
| Not completed | 38 | 29 | 21 |
| Withdrew: Withdrawal by subject | 24 | 15 | 8 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Withdrew: Decision by sponsor | 12 | 14 | 12 |
Bone pain data were captured as part of standard adverse event (AE) reporting.
| percentage of participants | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Percentage of Participants With Bone Pain (All Grades) in Cycle 1 | 46.6 (39.4 to 53.9) | 40.3 (33.4 to 47.5) | 42.5 (35.6 to 49.7) |
Bone pain data were captured as part of standard adverse event (AE) reporting.
| percentage of participants | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Cycle 2 (n=178, 180, 193) | 34.3 (27.3 to 41.7) | 34.4 (27.5 to 41.9) | 34.7 (28.0 to 41.9) |
| Cycle 3 (n=165, 176, 188) | 33.9 (26.8 to 41.7) | 34.1 (27.1 to 41.6) | 36.2 (29.3 to 43.5) |
| Cycle 4 (n=162, 169, 179) | 40.7 (33.1 to 48.7) | 40.2 (32.8 to 48.0) | 38.0 (30.9 to 45.5) |
| Across All Cycles (n=191, 196, 200) | 63.4 (56.1 to 70.2) | 59.2 (52.0 to 66.1) | 61.0 (53.9 to 67.8) |
Bone pain data were captured as part of standard adverse event reporting. Severe bone pain is defined as grade 3 or 4 according to common terminology criteria for adverse events (CTCAE) version 3 grading criteria: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening or disabling.
| percentage of participants | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Cycle 1 (n=191, 196, 200) | 4.7 (2.2 to 8.8) | 3.1 (1.1 to 6.5) | 4.5 (2.1 to 8.4) |
| Cycle 2 (n=178, 180, 193) | 1.1 (0.1 to 4.0) | 1.7 (0.3 to 4.8) | 0.0 (0.0 to 1.9) |
| Cycle 3 (n=165, 176, 188) | 1.8 (0.4 to 5.2) | 1.1 (0.1 to 4.0) | 0.0 (0.0 to 1.9) |
| Cycle 4 (n=162, 169, 179) | 1.9 (0.4 to 5.3) | 0.6 (0.0 to 3.3) | 0.0 (0.0 to 2.0) |
| Across All Cycles (n=191, 196, 200) | 5.8 (2.9 to 10.1) | 4.1 (1.8 to 7.9) | 4.5 (2.1 to 8.4) |
Participants completed a brief bone pain survey once per day for 5 days beginning the day they received their pegfilgrastim injection. The bone pain survey collected the severity of pain using a 0 (no pain) to 10 (worst pain) scale. Mean patient-reported bone pain values are the average of each participant's bone pain values across survey days 1-5 within each cycle. Across all cycles the mean is the average of each patient-reported bone pain value across all survey days 1-5 and across all cycles. An analysis of variance (ANOVA) model with treatment as explanatory term was used.
| units on a scale | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Cycle 1 (n=191, 196, 200) | 2.2 ± 0.2 | 1.8 ± 0.2 | 1.7 ± 0.1 |
| Cycle 2 (n=178, 180, 193) | 1.7 ± 0.2 | 1.3 ± 0.1 | 1.4 ± 0.1 |
| Cycle 3 (n=165, 176, 188) | 1.6 ± 0.2 | 1.3 ± 0.1 | 1.4 ± 0.1 |
| Cycle 4 (n=162, 169, 179) | 1.7 ± 0.2 | 1.2 ± 0.1 | 1.3 ± 0.1 |
| Across all Cycles (n=191, 196, 200) | 1.9 ± 0.1 | 1.5 ± 0.1 | 1.5 ± 0.1 |
Participants completed a brief bone pain survey once per day for 5 days beginning the day they received their pegfilgrastim injection. The bone pain survey collected the severity of pain using a 0 (no pain) to 10 (worst pain) scale. Maximum patient-reported bone pain is the maximum of each participant's bone pain values across survey Days 1-5 within each cycle. Across all cycles the maximum is the maximum of each patient-reported bone pain value across all survey days 1-5 and across all cycles. An ANOVA model with treatment as explanatory term was used.
| units on a scale | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Cycle 1 (n=191, 196, 200) | 3.9 ± 0.2 | 3.3 ± 0.2 | 3.0 ± 0.2 |
| Cycle 2 (n=178, 180, 193) | 3.0 ± 0.2 | 2.4 ± 0.2 | 2.6 ± 0.2 |
| Cycle 3 (n=165, 176, 188) | 2.7 ± 0.2 | 2.2 ± 0.2 | 2.5 ± 0.2 |
| Cycle 4 (n=162, 169, 179) | 2.8 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 |
| Across All Cycles (n=191, 196, 200) | 4.7 ± 0.2 | 4.2 ± 0.2 | 4.1 ± 0.2 |
Patient-reported bone pain AUC was calculated using the trapezoidal rule with bone pain scores from day 1 to 5 for each cycle. The AUC across cycles is the average of AUCs across the cycle.
| units on a scale * days | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Cycle 1 (n=191, 196, 200) | 9.3 ± 0.7 | 7.7 ± 0.6 | 7.0 ± 0.6 |
| Cycle 2 (n=178, 180, 193) | 7.3 ± 0.7 | 5.6 ± 0.6 | 5.9 ± 0.5 |
| Cycle 3 (n=165, 176, 188) | 6.8 ± 0.7 | 5.5 ± 0.6 | 6.1 ± 0.6 |
| Cycle 4 (n=162, 169, 179) | 7.2 ± 0.7 | 5.2 ± 0.6 | 5.6 ± 0.6 |
| Across All Cycles (n=191, 196, 200) | 8.0 ± 0.6 | 6.6 ± 0.5 | 6.3 ± 0.5 |
Severity was graded using CTCAE version 3. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal; • life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • congenital anomaly/birth defect; • other medically important serious event. The investigator assessed each adverse event for relatedness to investigational product(s) or other protocol-required therapies.
| participants | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD |
|---|---|---|---|
| Any adverse event | 188 | 192 | 194 |
| Worst grade of ≥ 2 | 164 | 169 | 168 |
| Worst grade of ≥ 3 | 74 | 73 | 63 |
| Worst grade of ≥ 4 | 18 | 30 | 20 |
| Serious adverse events | 34 | 30 | 14 |
| Fatal adverse events | 0 | 0 | 0 |
| AE leading to discontinuation from study | 3 | 5 | 3 |
| SAE leading to discontinuation from study | 1 | 3 | 2 |
| Any adverse event related to IP | 0 | 30 | 7 |
| SAE related to IP | 0 | 1 | 0 |
| AE related to IP leading to discontinuation of IP | 0 | 9 | 0 |
| SAE related to IP leading to discontinuation of IP | 0 | 1 | 0 |
| Any adverse event related to pegfilgrastim | 87 | 96 | 105 |
| SAE related to pegfilgrastim | 4 | 0 | 1 |
| AE related to / leading to discontinuation of Peg | 6 | 3 | 6 |
| SAE related to / leading to discontinuation of Peg | 1 | 0 | 0 |
Collected over From first dose of investigational product (naproxen or loratidine) or first dose of pegfilgrastim, whichever occurred first, until 30 days after last dose, up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| No Prophylactic Intervention | — | 34/196 (17.3%) | 184/196 (93.9%) |
| Naproxen 500mg BID | — | 30/193 (15.5%) | 190/193 (98.4%) |
| Loratadine 10mg QD | — | 14/198 (7.1%) | 193/198 (97.5%) |
| Event | No Prophylactic Intervention | Naproxen 500mg BID | Loratadine 10mg QD |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/196 | 6/193 | 3/198 |
| DehydrationMetabolism and nutrition disorders | 6/196 | 3/193 | 1/198 |
| SyncopeNervous system disorders | 1/196 | 4/193 | 0/198 |
| PyrexiaGeneral disorders | 3/196 | 3/193 | 2/198 |
| NauseaGastrointestinal disorders | 3/196 | 2/193 | 0/198 |
| VomitingGastrointestinal disorders | 3/196 | 2/193 | 0/198 |
| DiarrhoeaGastrointestinal disorders | 2/196 | 2/193 | 0/198 |
| SepsisInfections and infestations | 1/196 | 2/193 | 0/198 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/196 | 2/193 | 0/198 |
| NeutropeniaBlood and lymphatic system disorders | 2/196 | 0/193 | 2/198 |
| Event | No Prophylactic Intervention | Naproxen 500mg BID | Loratadine 10mg QD |
|---|---|---|---|
| FatigueGeneral disorders | 120/196 | 110/193 | 128/198 |
| NauseaGastrointestinal disorders | 98/196 | 118/193 | 100/198 |
| AlopeciaSkin and subcutaneous tissue disorders | 68/196 | 85/193 | 106/198 |
| ConstipationGastrointestinal disorders | 60/196 | 77/193 | 66/198 |
| DiarrhoeaGastrointestinal disorders | 67/196 | 75/193 | 71/198 |
| Bone painMusculoskeletal and connective tissue disorders | 56/196 | 55/193 | 63/198 |
| AnaemiaBlood and lymphatic system disorders | 42/196 | 60/193 | 40/198 |
| HeadacheNervous system disorders | 49/196 | 54/193 | 48/198 |
| VomitingGastrointestinal disorders | 32/196 | 43/193 | 29/198 |
| Decreased appetiteMetabolism and nutrition disorders | 36/196 | 34/193 | 39/198 |
Full analysis set included all participants based on the randomization treatment group who received primary prophylaxis with pegfilgrastim.
| Age, Continuous(years) | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD | Total |
|---|---|---|---|---|
| Mean | 54.8 ± 10.7 | 53.2 ± 11.7 | 54.6 ± 10.9 | 54.2 ± 11.1 |
| Sex: Female, Male(Participants) | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD | Total |
|---|---|---|---|---|
| Female | 191 | 196 | 200 | 587 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD | Total |
|---|---|---|---|---|
| Hispanic/Latino | 13 | 15 | 9 | 37 |
| Not Hispanic/Latino | 178 | 181 | 191 | 550 |
| Race/Ethnicity, Customized(participants) | No Prophylaxis | Naproxen 500 mg BID | Loratadine 10 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 3 | 3 | 1 | 7 |
| Black (or African American) | 33 | 27 | 23 | 83 |
| Multiple | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| White | 148 | 166 | 173 | 487 |
| Other | 5 | 0 | 2 | 7 |
Ran from Nov 2012 to primary completion in Mar 2015, 28 months.
Results were first posted in Mar 2016, 11 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 28 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naproxen · Loratadine